Ocular Therapeutix, Regeneron end collaboration for sustained-release aflibercept formula
Click Here to Manage Email Alerts
Ocular Therapeutix and Regeneron will no longer collaborate on the creation of a sustained-release formulation of aflibercept, according to a press release from Ocular Therapeutix.
The collaboration originated in 2016 to pursue development of products utilizing Ocular Theraeutix’s “sustained-release hydrogel technology” along with Regeneron’s “large molecule VEGF-targeting compounds” to address retinal diseases, according to the release.
“While we are sorry to see the collaboration end, we are grateful for having had the chance to work with a company like Regeneron and a molecule like aflibercept,” Antony Mattessich, president and CEO of Ocular Therapeutix, said in the release. “Most importantly, we learned a great deal about how to formulate our proprietary hydrogel with monoclonal antibodies and to administer them to the suprachoroidal space. This work could become a valuable strategic driver for our future pipeline.”
Read more about
Click Here to Manage Email Alerts